explore -WSS

explore

author：knowledge 2025-09-28 02:30:43 - browse：7

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Humana cuts profit projections as Medicare Advantage costs soar

WSS

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

EU regulator recommends expanding Mounjaro approval to obesity

Test for long Covid? Researchers find new clue in blood samples

How digital therapeutics firms are pivoting after Pear's bankruptcy

Research misconduct: Proposed new rules face resistance

A letter from the executive editor: STAT UnitedHealth investigation

entertainment

explore

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Humana cuts profit projections as Medicare Advantage costs soar

State Dept. review finds Biden bears some blame for Afghanistan failures

First transplant of an entire human eye performed

How one medical school became remarkably diverse

Prior authorization will have to move faster under new Biden rule

Novavax promises a turnaround & Lilly roils the obesity market

AI generated plenty of interest at JPM but not a lot of trust

Continuity nursing helped my family in our darkest PICU moments

FDA clears AI tool for detecting skin cancer

knowledge

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Dewpoint Therapeutics lays off staff after losing partnerships

Prior authorization will have to move faster under new Biden rule

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Study suggests Covid rebound is far more common with Paxlovid than without

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Wikipedia

Wikipedia

explore

explore